Webcast

Clinical Applications of Recently Approved Biomarkers of Acute Kidney Injury

  • Credit:1.0 ACCENT
  • Duration: 63 minutes
  • Date:NOV.19.2014 2:00 PM - 03:00 PM

Price: $0.00

Member Price: $0.00

Rating: Member Average

DESCRIPTION

In September, the FDA cleared for marketing the first laboratory assay for assessing a critically ill patient’s risk of developing moderate to severe acute kidney injury (AKI). This new test comes to market at a time when clinical trial data is providing a clearer picture of the relationship between AKI and both short-term (death, prolonged hospitalization) and long-term risk for cardiovascular events and chronic kidney disease (CKD). Indeed AKI is a major risk factor for progression toward and worsening of CKD.

TARGET AUDIENCE

This program is designed for laboratorians, kidney specialists, pathologists, laboratory directors, clinicians, diagnostic manufacturers, and other medical professionals involved in the diagnosis or management of patients with acute kidney injury or kidney disease.

SPEAKER

John A. Kellum, MD, MCCM, Professor of Critical Care Medicine, Medicine, Bioengineering, and Clinical and Translational Science, Vice Chair for Research in the Department of Critical Care Medicine, and Director of the Center for Critical Care Nephrology for the Clinical Research Investigation and Systems Modeling of Acute illness (CRISMA) Center at the University of Pittsburgh, Pittsburgh, PA

Dr. Kellum is the principal investigator and co-investigator on several NIH-funded studies in clinical and basic science research including grants from NHLBI, NIGMS, NIDDK and HRSA. His research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, acute kidney injury and renal replacement therapy), sepsis and multi-organ failure, brain death and organ donor management and translational research. He has authored more than 300 publications and has won several awards for teaching. He lectures widely and has given more than 400 seminars and invited lectures related to his research.

Program

In September, the FDA cleared for marketing the first laboratory assay for assessing a critically ill patient’s risk of developing moderate to severe acute kidney injury (AKI). This new test comes to market at a time when clinical trial data is providing a clearer picture of the relationship between AKI and both short-term (death, prolonged hospitalization) and long-term risk for cardiovascular events and chronic kidney disease (CKD). Indeed AKI is a major risk factor for progression toward and worsening of CKD.

To assess kidney damage, clinicians traditionally have relied on clinical tests based on creatinine, which may not rise until 24 to 48 hours after an AKI episode. Relying on these tests may lead to delays in diagnosis, missed opportunities to minimize damage, and worse patient outcomes.

Join AACC for this free 60-minute webinar and learn how recently cleared AKI biomarkers can be used to potentially prevent some of these adverse outcomes through earlier AKI diagnosis and therapeutic interventions and also discover the unique mechanisms that are behind these biomarkers. Kidney disease expert and researcher, Dr. John Kellum, will:

  • Review the definitions of AKI and staging and their relationship to outcomes
  • Describe the major risk factors for and consequences of AKI
  • Provide an overview of AKI biomarkers and where they are used in the various stages of the process that leads to AKI
  • Review the underlying biology associated with these new markers and what it means for our understanding of the pathogenesis of AKI
  • Discuss current best practices for detecting AKI and how recently approved tests may fit into those practices.

Continuing Education

Obtain Your CE Here After Viewing the Program

By claiming continuing education credit for this activity, you are affirming that you have participated in this activity in its entirety.

System Requirements

Click here for a full list of system requirements.

Self Test - Test your system compatibility ahead of time. If you cannot get WebEx to launch, call WebEx technical support at 866.229.3239.

Ortho Clinical Diagnostics